Core Insights - Minovia Therapeutics has been granted two new U.S. patents that enhance its intellectual property portfolio for its Mitochondrial Augmentation Therapy (MAT) platform, which targets primary mitochondrial diseases and severe renal diseases [1][2]. Patent Details - U.S. Patent No. 12,502,408 covers Minovia's MNV-201 program, which utilizes autologous hematopoietic stem cells enriched with placental-derived mitochondria for treating primary mitochondrial diseases [3]. - U.S. Patent No. 12,329,781 pertains to the application of mitochondrial augmentation technology for renal diseases, including renal tubulopathy, kidney insufficiency, and chronic kidney disease (CKD), thus broadening the MAT platform's therapeutic scope [4]. Company Strategy - The new patents reinforce Minovia's strategy to develop transformative therapies for patients with high unmet medical needs, emphasizing the versatility of the MAT platform across various serious disease areas [5]. - The company is advancing its clinical and preclinical programs while expanding its global patent estate to support future development and partnership opportunities [5]. Business Combination - Minovia has entered into a definitive business combination agreement with Launch One Acquisition Corp., with the transaction expected to close in the first half of 2026, after which the combined entity will operate as Minovia Therapeutics and trade on Nasdaq under a new ticker symbol [6]. Product Overview - MNV-201 is a first-in-class cell therapy that aims to restore organ function by adding healthy mitochondria to a patient's own stem cells, showing a strong safety profile and multi-system benefits in early-stage clinical studies for Pearson Syndrome [7]. Company Background - Minovia Therapeutics is a clinical-stage biotechnology company based in Haifa, Israel, focused on developing treatments for mitochondrial diseases and age-related decline, with plans to expand operations to the U.S. [8].
Minovia Therapeutics Announces Two New U.S. Patents Granted, Strengthening Its Mitochondrial Augmentation Therapy Platform